Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma

Summary

The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.

Timeline

Start

2014-06

Primary completion

2019-08

Completion

2019-11

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The primary endpoint was 1-year survival for patients treated with CTX. PMID 34086514 ↗

paper The 1-year survival rate was 34.7% (95% CI 21.8 - 47.9) with CTX PMID 34086514 ↗

Publications

• Petersen PC, Petersen LN, Vogelius I, Bjerregaard JK, Baeksgaard L. A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Acta Oncol. 2021 Jul;60(7):948-953. doi: 10.1080/0284186X.2021.1928281. Epub 2021 Jun 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	625 mg/m2	Oral
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Docetaxel	Small molecule	60 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	50 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	130 mg/m2	—

Indications